105 related articles for article (PubMed ID: 16832603)
1. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ishill N; Sweeney SM; Deluca JK; Schwartz L; Bacik J; Motzer RJ
Invest New Drugs; 2006 Nov; 24(6):543-6. PubMed ID: 16832603
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
Gartner EM; Silverman P; Simon M; Flaherty L; Abrams J; Ivy P; Lorusso PM
Breast Cancer Res Treat; 2012 Feb; 131(3):933-7. PubMed ID: 22083229
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced alopecia in rodent models.
Jimenez JJ; Roberts SM; Mejia J; Mauro LM; Munson JW; Elgart GW; Connelly EA; Chen Q; Zou J; Goldenberg C; Voellmy R
Cell Stress Chaperones; 2008; 13(1):31-8. PubMed ID: 18347939
[TBL] [Abstract][Full Text] [Related]
5. The Interplay Between HIF-1α and EZH2 in Lung Cancer and Dual-Targeted Drug Therapy.
Wang J; Yang C; Xu H; Fan X; Jia L; Du Y; Liu S; Wang W; Zhang J; Zhang Y; Wang X; Liu Z; Bao J; Li S; Yang J; Wu C; Tang J; Chen G; Wang L
Adv Sci (Weinh); 2024 Feb; 11(7):e2303904. PubMed ID: 38072662
[TBL] [Abstract][Full Text] [Related]
6. Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review.
Fakhri S; Moradi SZ; Faraji F; Kooshki L; Webber K; Bishayee A
Cancer Metastasis Rev; 2024 Mar; 43(1):501-574. PubMed ID: 37792223
[TBL] [Abstract][Full Text] [Related]
7. The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies.
Jawad SF; Altalbawy FMA; Hussein RM; Fadhil AA; Jawad MA; Zabibah RS; Taraki TY; Mohan CD; Rangappa KS
Cancer Metastasis Rev; 2024 Mar; 43(1):5-27. PubMed ID: 37552389
[TBL] [Abstract][Full Text] [Related]
8. LZY3016, a novel geldanamycin derivative, inhibits tumor growth in an MDA-MB-231 xenograft model.
Li Z; Jia L; Tang H; Shen Y; Shen C
RSC Adv; 2023 May; 13(20):13586-13591. PubMed ID: 37152572
[TBL] [Abstract][Full Text] [Related]
9. From Natural Sources to Synthetic Derivatives: The Allyl Motif as a Powerful Tool for Fragment-Based Design in Cancer Treatment.
Astrain-Redin N; Sanmartin C; Sharma AK; Plano D
J Med Chem; 2023 Mar; 66(6):3703-3731. PubMed ID: 36858050
[TBL] [Abstract][Full Text] [Related]
10. HIF: a master regulator of nutrient availability and metabolic cross-talk in the tumor microenvironment.
Missiaen R; Lesner NP; Simon MC
EMBO J; 2023 Mar; 42(6):e112067. PubMed ID: 36808622
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).
Li ZN; Luo Y
Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36367182
[TBL] [Abstract][Full Text] [Related]
12. Chaperone-assisted E3 ligase CHIP: A double agent in cancer.
Kumar S; Basu M; Ghosh MK
Genes Dis; 2022 Nov; 9(6):1521-1555. PubMed ID: 36157498
[TBL] [Abstract][Full Text] [Related]
13. Novel Drugs with High Efficacy against Tumor Angiogenesis.
Qi S; Deng S; Lian Z; Yu K
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805939
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of geldanamycin-ferulic acid conjugate as a potent Hsp90 inhibitor.
Li Z; Jia L; Tang H; Shen Y; Shen C
RSC Adv; 2019 Dec; 9(72):42509-42515. PubMed ID: 35542888
[TBL] [Abstract][Full Text] [Related]
16. Heat Shock Proteins and HSF1 in Cancer.
Cyran AM; Zhitkovich A
Front Oncol; 2022; 12():860320. PubMed ID: 35311075
[TBL] [Abstract][Full Text] [Related]
17. Inflammation and Myeloid Cells in Cancer Progression and Metastasis.
Deng J; Fleming JB
Front Cell Dev Biol; 2021; 9():759691. PubMed ID: 35127700
[TBL] [Abstract][Full Text] [Related]
18. HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies.
Wang X; Du ZW; Xu TM; Wang XJ; Li W; Gao JL; Li J; Zhu H
Front Oncol; 2021; 11():785111. PubMed ID: 35004308
[TBL] [Abstract][Full Text] [Related]
19. Targeting immune cell metabolism in kidney diseases.
Basso PJ; Andrade-Oliveira V; Câmara NOS
Nat Rev Nephrol; 2021 Jul; 17(7):465-480. PubMed ID: 33828286
[TBL] [Abstract][Full Text] [Related]
20. Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides.
Nonaka M; Mabashi-Asazuma H; Jarvis DL; Yamasaki K; Akama TO; Nagaoka M; Sasai T; Kimura-Takagi I; Suwa Y; Yaegashi T; Huang CT; Nishizawa-Harada C; Fukuda MN
PLoS One; 2021; 16(1):e0241157. PubMed ID: 33406123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
